Hong Kong Stock Movement: INNOGEN-B rises 12.94%, driven by the dual benefits of inclusion in the Stock Connect and the medical insurance catalog

Hong Kong Stock Movement INNOGEN-B rose 12.94%. Based on recent key news: On December 8, INNOGEN-B's H shares were included in the eligible securities list for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, enhancing the investor base and trading volume, driving the stock price up. Source: Zhitong Finance On December 8, INNOGEN-B's core product, Isu-Paglutide α, was successfully included in the latest version of the National Medical Insurance Drug List in China, boosting market confidence. Source: Jingji Tong News Agency On December 9, INNOGEN-B's stock price continued to rise due to the market's positive reaction to its inclusion in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect. Source: Huigang Communications, the pharmaceutical industry shows great potential for innovative drug development, with significant capital inflow. Stocks with High Trading Volume in the Industry Innovent Biologics fell 0.89%. Based on recent key news: On December 8, Innovent Biologics announced that its seven innovative products were successfully included in the new version of the National Medical Insurance Drug List, covering areas such as oncology and cardiovascular diseases. After the announcement, the stock price fell. Zhitong Finance reported that investors are concerned that Eli Lilly's Tezepelumab entering the medical insurance list may pressure Innovent Biologics' Ma Shidu peptide sales. On December 9, JP Morgan released a report indicating that Innovent Biologics' stock price fell by about 7%, related to the results of the National Medical Insurance Drug List negotiations. Investors are worried that Innovent Biologics may significantly reduce the prices of small molecule inhibitor drugs to gain medical insurance coverage. On December 10, UBS released a research report stating that Innovent Biologics was included in the Hang Seng Index, expecting rapid growth in new product sales by 2026, maintaining a "Buy" rating. The pharmaceutical sector has performed poorly recently, and policy changes need to be monitored. CanSino Biologics fell 2.85%. Based on recent key news: On December 7, CanSino Biologics announced that its five new drugs were successfully included in the 2025 version of the National Medical Insurance Drug List, expected to be officially implemented on January 1, 2026. This news raised market expectations for the company's future sales growth; however, the stock price still declined. On December 9, CMB International published a report stating that more new drugs entering the medical insurance list would enhance the overall R&D return rate of the innovative drug industry and provide incremental release space for companies like CanSino Biologics. Nevertheless, the market still has doubts about the actual implementation and payment situation in the short term. On December 8, CanSino Biologics announced that its five new drugs had been included in the latest version of the National Medical Insurance Drug List, further consolidating the company's leading position in the innovative drug field, but the stock price did not rise as a result. The innovative drug development potential in the pharmaceutical industry is significant. BeiGene fell 1.46%. Based on recent key news: On December 8, the National Healthcare Security Administration released a new version of the drug list, and two of BeiGene's drugs were included in the commercial insurance innovative drug list. This move may affect its market competitiveness and sales expectations, leading to stock price fluctuations. Source: Zhitong Finance On December 8, CITIC Securities' research report pointed out that the success rate of national medical insurance negotiations reached a historical high, and policies encourage the development of innovative drugs. BeiGene is viewed positively, and market expectations for its future growth have increased Source: CITIC Construction Investment On December 8th, BeiGene's cancer therapy Brukinsa is favored by analysts, who expect it to continue boosting global sales. Analysts have given it a buy rating with a target price of HKD 252. Source: UOB Kay Hian Innovation drug industry policy support strengthens, market expectations are positive. Stocks ranked among the top in industry market capitalization Kalon Biotech-B fell 4.45%. Based on recent news, On December 8th, the commercial insurance catalog included high-value innovative drugs, and Kalon Biotech's CAR-T therapy was selected, enjoying a discount of 15% to 50%, driving stock price fluctuations. The introduction of the commercial insurance catalog provides a new path for innovative drug payments, and companies are actively negotiating cooperation with insurance companies to promote the implementation of policies. Source: Zhitong Finance On December 8th, Kalon Biotech partnered with Crescent to develop next-generation combination therapies, with rapid technological iteration and intensified competition. Although the PD-1/VEGF dual antibody + ADC momentum is strong, clinical progress is in the early stages, and safety and synergistic effects need to be verified. Source: Wall Street Insights The innovative drug payment ecosystem is improving, activating market vitality